Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  brentuximab vedotin
Find trials that include:  Any drugs shown
Results 1-25 of 35 for your search:
Start Over
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-014, NCI-2013-00462, 2012-002751-42, NCT01777152
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-204, NCI-2016-00839, 2015-005053-12, NCT02684292
Brentuximab Vedotin and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ5050, NCI-2012-01926, NCT01657331
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, NCT01771107
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: AHOD1221, NCI-2013-00107, COG-AHOD1221, NCT01780662
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 17413, NCI-2013-02359, 818280, NCT01994850
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 45 and under
Trial IDs: NYMC 564, NCI-2015-01809, NCT02098512
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9111, NCI-2014-01782, NCT02227199
Mocetinostat and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-232, NCI-2015-00780, NCT02429375
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-025, NCI-2015-01867, NCT02572167
A Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-436, NCI-2016-00313, 2015-003286-28, NCT02581631
Ceritinib with Brentuximab Vedotin in Treating Patients with ALK-Positive Anaplastic Large Cell Lymphoma
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 9522, NCI-2016-00396, NCT02729961
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Stage II-IV Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: NU 11H01, NCI-2011-00684, NCT01476410
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: SGN35-015, NCI-2012-02209, NCT01716806
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: HLHR13, NCI-2013-01123, NCT01920932
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-017, NCI-2013-01726, NCT01925612
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Brentuximab Vedotin Maintenance after Donor Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 2013-0351, NCI-2014-01593, NCT02169505
Brentuximab Vedotin, Doxorubicin Hydrochloride, and Dacarbazine in Treating Patients with Previously Untreated Stage I-IIB Non-bulky Classical Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-196, NCI-2015-01592, 35-IST-029, NCT02505269
Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Mature T Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE1415, NCI-2016-00018, NCT02588651
Brentuximab Vedotin, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1507953455, NCI-2015-01468, T502a, NCT02623920
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-023, NCI-2016-00245, NCT02594163
Ibrutinib and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 15334, NCI-2016-00176, NCT02744612
Start Over